COVID-19, severe asthma, and biologics

García-Moguel, Ismael; Campos, R; Charterina, Sergio Alonso; Rodríguez, Consuelo; Crespo, Jesús F.

doi:10.1016/j.anai.2020.06.012

Cited by 32 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few reports linked asthma to COVID-19 severity; however, in most of the studies, asthma was not identified as a risk factor for severe illness ( Morais-Almeida et al, 2019 ). Moreover, cases of COVID-19 patients with severe asthma were reported to have a good outcome despite expectations of severe infection and poor prognosis in this subset of patients ( Garcia-Moguel et al, 2020 ).…”

Section: The Association Between Covid-19 and The Most Common Chronicmentioning

confidence: 99%

The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities

Alyammahi

Abdin

Alhamad

et al. 2021

Infection, Genetics and Evolution

View full text Add to dashboard Cite

The devastating pandemic of coronavirus disease 2019 (COVID-19) has caused thousands of deaths and left millions of restless patients suffering from its complications. Increasing data indicate that the disease presents in a severe form in patients with pre-existing chronic conditions like cardiovascular diseases, diabetes, respiratory system diseases, and renal diseases. This indicates that these patients seem to be more susceptible to COVID-19 and have higher mortality rates compared to patients with no comorbid conditions. Several factors can explain the heightened susceptibility to and fatal presentation of COVID-19 in these patients, for example, the enhanced expression of the angiotensin-converting enzyme-2 receptor (ACE2) in specific organs, cytokine storm, and drug interactions contribute to the increased morbidity and mortality. Adding to the findings that individuals with pre-existing conditions may be more susceptible to COVID-19, it has also been shown that COVID-19 can induce chronic diseases in previously healthy patients. Therefore, understanding the interlinked relationship between COVID-19 and chronic diseases helps in optimizing the management of susceptible patients. This review comprehensively described the molecular mechanisms that contribute to worse COVID-19 prognosis in patients with pre-existing comorbidities such as diabetes, cardiovascular diseases, respiratory diseases, gastrointestinal and renal diseases, blood disorders, autoimmune diseases and finally, obesity. It also focused on how COVID-19 could, in some cases, lead to chronic conditions as a result of long-term multi-organ damage. Lastly, this work carefully discusses the tailored management plans for each specific patient population, aiming to achieve the best therapeutic outcome with minimum complications.

show abstract

Section: The Association Between Covid-19 and The Most Common Chronicmentioning

confidence: 99%

The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities

Alyammahi

Abdin

Alhamad

et al. 2021

Infection, Genetics and Evolution

View full text Add to dashboard Cite

show abstract

“…Recently obtained data has shown that in patients with COVID-19, eosinopenia developed during the infection. This data suggests that an elevation of the number of eosinophils could indicate an improvement of this disease [7].…”

Section: Introductionmentioning

confidence: 60%

Apoptosis of Eosinophil Granulocytes

Zustakova

Kratochvilova

Sláma

2020

Biology

View full text Add to dashboard Cite

In the past 10 years, the number of people in the Czech Republic with allergies has doubled to over three million. Allergic pollen catarrh, constitutional dermatitis and asthma are the allergic disorders most often diagnosed. Genuine food allergies today affect 6–8% of nursing infants, 3–5% of small children, and 2–4% of adults. These disorders are connected with eosinophil granulocytes and their apoptosis. Eosinophil granulocytes are postmitotic leukocytes containing a number of histotoxic substances that contribute to the initiation and continuation of allergic inflammatory reactions. Eosinophilia results from the disruption of the standard half-life of eosinophils by the expression of mechanisms that block the apoptosis of eosinophils, leading to the development of chronic inflammation. Glucocorticoids are used as a strong acting anti-inflammatory medicine in the treatment of hypereosinophilia. The removal of eosinophils by the mechanism of apoptosis is the effect of this process. This work sums up the contemporary knowledge concerning the apoptosis of eosinophils, its role in the aforementioned disorders, and the indications for the use of glucocorticoids in their related therapies.

show abstract

“…Supporting this claim, Lommatzsch demonstrated that omalizumab could safely be continued during active COVID‐19 infection in a patient with allergic asthma 1 . There are other reports that treatment with benralizumab 2 and dupilumab 3 are not associated with significant negative impact. We had similar experience in a young patient with severe asthma who had previously been treated with dupilumab.…”

Section: Figurementioning

confidence: 90%

Dupilumab, severe asthma airway responses, and SARS‐CoV‐2 serology

Bhalla

Mukherjee

Radford

et al. 2020

Allergy

View full text Add to dashboard Cite

There is paucity of evidence assessing immune responses to COVID‐19 in severe asthmatics treated with biologics. Recent guidelines recommend continuing these agents (as clinically indicated) to maintaining asthma control. Supporting this claim, Lommatzsch demonstrated that omalizumab could safely be continued during active COVID‐19 infection in a patient with allergic asthma. 1 There are other emerging reports that show that treatment with benralizumab 2 and dupilumab 3 is not associated with significant negative impact. We had similar experience in a young patient with severe asthma treated with dupilumab.

show abstract

COVID-19, severe asthma, and biologics

Cited by 32 publications

References 15 publications

The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities

The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities

Apoptosis of Eosinophil Granulocytes

Dupilumab, severe asthma airway responses, and SARS‐CoV‐2 serology

Contact Info

Product

Resources

About